<DOC>
	<DOCNO>NCT02231918</DOCNO>
	<brief_summary>Study determine pharmacokinetics ( PK ) pramipexole ( PPX ) administration single dose orally ( p.o . ) pediatric patient diagnosis RLS</brief_summary>
	<brief_title>Study Investigate Pharmacokinetics ( PK ) Pramipexole Pediatric Patients Who Are Individually Optimized Stable Pramipexole Doses Treatment Idiopathic Restless Legs Syndrome ( RLS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>1 . Male female patient age 6 year 16 year ( two age group , 6 11 year 12 16 year , number patient possible ) 2 . Diagnosis idiopathic Restless Legs Syndrome ( RLS ) accord Clinical RLS criterion International Restless Legs Syndrome Study Group ( IRLSSG ) All 4 follow criterion must present : An urge move leg , usually accompany cause uncomfortable unpleasant sensation leg . ( Sometimes urge move present without uncomfortable sensation sometimes arm body part involve addition leg . ) The urge move unpleasant sensation begin worsen period rest inactivity lie sit The urge move unpleasant sensation partially totally relieved movement , walk stretch , least long activity continue The urge move unpleasant sensation worse even night day occur even night . ( When symptom severe , worsen night may noticeable must previously present . ) 3 . Must meet 4 diagnostic criterion adult RLS ( see inclusion criterion No . 2 ) either : 1 . The child must able describe leg discomfort word 2 . The child must 2 3 following : Sleep disturbance Periodic Limb Movements During Sleep ( PLMS ) index &gt; 5 per hour sleep , A biological parent sibling definite RLS 4 . Written inform consent consistent International Conference Harmonisation ( ICH ) / Good Clinical Practice ( GCP ) Local Institutional Review Board requirement child obtain prior study procedure perform 5 . Ability willingness comply study treatment regimen attend study assessment 6 . Must PPX treatment even maintenance dose minimum 7 day prior entry study determine investigator 7 . A patient take PPX even maintenance dose may return repeat screen patient successfully switch restabilized even PPX maintenance dose Exclusion criterion : 1 . Any woman childbearing potential positive serum pregnancy test screen 2 . Any woman childbearing potential use medically accept method contraceptive ( IntraUterine Device , oral , implantable , injectable contraceptive estrogen patch , double barrier method [ spermicide + diaphragm ] , abstinence discretion investigator ) 3 . Patients clinically significant renal disease serum creatinine level great 1.0 mg/dL screen 4 . Any following lab result screen : Hemoglobin ( Hgb ) low limit normal ( LLN ) , determine clinically significant Basal thyroid stimulate hormone ( TSH ) , triiodothyronine ( T3 ) thyroxine ( T4 ) clinically significantly ( investigator 's discretion ) normal range screening ( cause substitution therapy accord investigator 's opinion ) Patients clinically significant abnormality laboratory parameter screen investigator 's discretion 5 . Other clinically significant metabolicendocrine , hematological , gastrointestinal disease , pulmonary disease ( severe asthma ) opinion investigator would preclude patient participate study 6 . History clinical sign neurological disease potential secondarily cause RLS symptom 7 . Presence sleep disorder Rapid Eye Movement ( REM ) sleep behavior disorder , narcolepsy , sleep apnea syndrome 8 . History schizophrenia psychotic disorder , history mental disorder , present Axis I psychiatric disorder accord Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV ) require medical therapy 9 . History of/or clinical sign epilepsy seizure feverrelated seizure early childhood 10 . History of/or clinical sign malignant neoplasm include suspicious undiagnosed skin lesion ( may melanoma ) , melanoma , history melanoma 11 . Any condition , opinion investigator , would interfere evaluation result constitute health hazard patient 12 . Allergic response PPX inactive ingredient tablet formulation 13 . Had previous treatment dopamine agonists PPX within 14 day prior baseline visit 14 . Had medical treatment RLS besides study medication within 14 day prior baseline visit 15 . Had withdrawal symptom medication screen baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>